Table 2.
Multivariate analysis
| HR | 95% CI | p value | |
|---|---|---|---|
| OS | |||
| PTCy alone | Reference | ||
| PT-Cy + 1 drug | 0.72 | 0.40–1.30 | 0.27 |
| PT-Cy + 2 drugs | 0.49 | 0.26–0.93 | 0.03 |
| Age (per 10 years) | 1.11 | 0.97–1.28 | 0.18 |
| AML vs. ALL | 0.60 | 0.39–0.91 | 0.02 |
| Year of Tx | 0.99 | 0.88–1.12 | 0.90 |
| UD vs. MSD | 0.95 | 0.66–1.36 | 0.77 |
| Disease status | |||
| CR1 | Reference | ||
| CR2/C3 | 1.7 | 1.07–2.70 | 0.02 |
| Active disease | 2.48 | 1.71–3.59 | < 0.001 |
| RIC vs. MAC | 1.20 | 0.83–1.74 | 0.34 |
| PB vs. BM | 1.13 | 0.69–1.83 | 0.63 |
| In vivo TCD | 1.07 | 0.72–1.60 | 0.73 |
| Patient positive CMV serology | 1.07 | 0.73–1.58 | 0.73 |
| Donor positive CMV serology | 1.17 | 0.81–1.71 | 0.40 |
| Center (frailty) | 0.25 | ||
| GRFS | |||
| PTCy alone | Reference | ||
| PT-Cy + 1 drug | 0.72 | 0.45–1.16 | 0.18 |
| PT-Cy + 2 drugs | 0.51 | 0.31–0.84 | 0.007 |
| Age (per 10 years) | 0.96 | 0.87–1.07 | 0.48 |
| AML vs. ALL | 0.89 | 0.62–1.26 | 0.50 |
| Year of Tx | 0.97 | 0.88–1.08 | 0.60 |
| UD vs. MSD | 1.04 | 0.78–1.40 | 0.77 |
| Disease status | |||
| CR1 | Reference | ||
| CR2/C3 | 1.27 | 0.85–1.89 | 0.24 |
| Active disease | 2.18 | 1.61–2.95 | < 0.001 |
| RIC vs. MAC | 1.32 | 0.98–1.77 | 0.07 |
| PB vs. BM | 1.30 | 0.87–1.94 | 0.20 |
| In vivo TCD | 0.83 | 0.60–1.16 | 0.27 |
| Patient positive CMV serology | 0.95 | 0.69–1.31 | 0.77 |
| Donor positive CMV serology | 1.20 | 0.88–1.63 | 0.26 |
| Center (frailty) | 0.91 | ||
| LFS | |||
| PTCy alone | Reference | ||
| PT-Cy + 1 drug | 0.97 | 0.57–1.63 | 0.90 |
| PT-Cy + 2 drugs | 0.65 | 0.37–1.12 | 0.12 |
| Age (per 10 years) | 1.09 | 0.97–1.23 | 0.17 |
| AML vs. ALL | 0.68 | 0.46–0.99 | 0.04 |
| Year of Tx | 1 | 0.89–1.11 | 0.94 |
| UD vs. MSD | 0.92 | 0.659–1.27 | 0.60 |
| Disease status | |||
| CR1 | Reference | ||
| CR2/C3 | 1.64 | 1.07–2.51 | 0.02 |
| Active disease | 2.49 | 1.78–3.47 | < 0.001 |
| RIC vs. MAC | 1.255 | 0.9–1.75 | 0.18 |
| PB vs. BM | 0.94 | 0.61–1.45 | 0.78 |
| In vivo TCD | 1.07 | 0.75–1.54 | 0.70 |
| Patient positive CMV serology | 0.98 | 0.69–1.39 | 0.93 |
| Donor positive CMV serology | 1.24 | 0.89–1.74 | 0.21 |
| Center (frailty) | 0.91 | ||
| Acute GvHD II-IV | |||
| PTCy alone | Reference | ||
| PT-Cy + 1 drug | 0.62 | 0.29–1.36 | 0.23 |
| PT-Cy + 2 drugs | 1.40 | 0.65–3.01 | 0.38 |
| Age (per 10 years) | 1.01 | 0.87–1.18 | 0.90 |
| AML vs. ALL | 0.53 | 0.33–0.85 | 0.008 |
| Year of Tx | 0.91 | 0.80–1.04 | 0.16 |
| UD vs. MSD | 1.66 | 1.06–2.60 | 0.03 |
| Disease status | |||
| CR1 | Reference | ||
| CR2/C3 | 0.62 | 0.32–1.19 | 0.15 |
| Active disease | 1.14 | 0.71–1.84 | 0.59 |
| RIC vs. MAC | 1.72 | 1.10–2.70 | 0.02 |
| PB vs. BM | 1.59 | 0.83–3.02 | 0.16 |
| In vivo TCD | 1.18 | 0.74–1.89 | 0.48 |
| Patient positive CMV serology | 0.74 | 0.47–1.15 | 0.18 |
| Donor positive CMV serology | 1.78 | 1.13–2.79 | 0.01 |
| Center (frailty) | 0.23 | ||
| Chronic GvHD | |||
| PTCy alone | Reference | ||
| PT-Cy + 1 drug | 0.60 | 0.27–1.37 | 0.23 |
| PT-Cy + 2 drugs | 0.52 | 0.22–1.23 | 0.14 |
| Age (per 10 years) | 0.90 | 0.76–1.05 | 0.18 |
| AML vs. ALL | 1.01 | 0.58–1.75 | 0.97 |
| Year of Tx | 0.97 | 0.82–1.14 | 0.69 |
| UD vs. MSD | 0.99 | 0.64–1.54 | 0.96 |
| Disease status | |||
| CR1 | Reference | ||
| CR2/C3 | 0.52 | 0.24–1.09 | 0.08 |
| Active disease | 0.84 | 0.47–1.48 | 0.54 |
| RIC vs. MAC | 1.01 | 0.63–1.62 | 0.96 |
| PB vs. BM | 2.41 | 1.19–4.89 | 0.01 |
| In vivo TCD | 0.59 | 0.37–0.96 | 0.03 |
| Patient positive CMV serology | 0.88 | 0.55–1.43 | 0.61 |
| Donor positive CMV serology | 0.86 | 0.53–1.39 | 0.53 |
| Center (frailty) | 0.93 | ||
| Extensive chronic GvHD | |||
| PTCy alone | Reference | ||
| PT-Cy + 1 drug | 0.57 | 0.21–1.56 | 0.27 |
| PT-Cy + 2 drugs | 0.25 | 0.08–0.84 | 0.02 |
| Age (per 10 years) | 0.76 | 0.63–0.96 | 0.02 |
| AML vs. ALL | 1.64 | 0.65–4.16 | 0.30 |
| Year of Tx | 1 | 0.79–1.26 | 0.98 |
| UD vs. MSD | 1.26 | 0.68–2.33 | 0.47 |
| Disease status | |||
| CR1 | Reference | ||
| CR2/C3 | 0.56 | 0.19–1.63 | 0.29 |
| Active disease | 1.24 | 0.57–2.68 | 0.59 |
| RIC vs. MAC | 1.43 | 0.72–2.84 | 0.30 |
| PB vs. BM | 4.57 | 1.61–12.99 | 0.004 |
| In vivo TCD | 0.23 | 0.01–0.54 | < 0.001 |
| Patient positive CMV serology | 0.92 | 0.46–1.80 | 0.80 |
| Donor positive CMV serology | 0.76 | 0.38–1.55 | 0.45 |
| Center (frailty) | 0.94 | ||
| Relapse | |||
| PTCy alone | Reference | ||
| PT-Cy + 1 drug | 1.12 | 0.59–2.13 | 0.73 |
| PT-Cy + 2 drugs | 0.82 | 0.42–1.61 | 0.57 |
| Age (per 10 years) | 1.03 | 0.89–1.19 | 0.69 |
| AML vs. ALL | 0.97 | 0.59–1.6 | 0.91 |
| Year of Tx | 1.03 | 0.90–1.18 | 0.64 |
| UD vs. MSD | 0.87 | 0.58–1.30 | 0.50 |
| Disease status | |||
| CR1 | Reference | ||
| CR2/C3 | 1.64 | 0.97–2.80 | 0.07 |
| Active disease | 2.42 | 1.60–3.66 | < 0.001 |
| RIC vs. MAC | 1.18 | 0.78–1.77 | 0.44 |
| PB vs. BM | 0.83 | 0.50–1.38 | 0.47 |
| In vivo TCD | 0.89 | 0.57–1.39 | 0.61 |
| Patient positive CMV serology | 0.71 | 0.46–1.08 | 0.11 |
| Donor positive CMV serology | 1.34 | 0.88–2.04 | 0.17 |
| Center (frailty) | 0.92 | ||
| NRM | |||
| PTCy alone | Reference | ||
| PT-Cy + 1 drug | 0.69 | 0.27–1.73 | 0.42 |
| PT-Cy + 2 drugs | 0.358 | 0.13–0.99 | 0.05 |
| Age (per 10 years) | 1.195 | 0.96–1.48 | 0.11 |
| AML vs. ALL | 0.353 | 0.19–0.67 | 0.001 |
| Year of Tx | 0.95 | 0.78–1.15 | 0.60 |
| UD vs. MSD | 1.022 | 0.58–1.81 | 0.94 |
| Disease status | |||
| CR1 | Reference | ||
| CR2/C3 | 1.63 | 0.78–3.38 | 0.19 |
| Active disease | 2.949 | 1.65–5.27 | < 0.001 |
| RIC vs. MAC | 1.339 | 0.74–2.42 | 0.33 |
| PB vs. BM | 1.247 | 0.56–2.78 | 0.59 |
| In vivo TCD | 1.47 | 0.78–2.75 | 0.23 |
| Patient positive CMV serology | 2.042 | 1.03–4.04 | 0.04 |
| Donor positive CMV serology | 1.038 | 0.58–1.87 | 0.90 |
| Center (frailty) | 0.29 | ||
HR hazard ratio, CI confidence interval, aGVHD acute graft-versus-host disease, cGVHD chronic GVHD, NRM non-relapse mortality, OS overall survival, LFS leukemia-free survival, GRFS GvHD-free relapse-free survival, MAC myeloablative, RIC reduced intensity conditioning regimen, PTCy post-transplant cyclophosphamide, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, Tx transplant, UD unrelated donor, MSD matched sibling donor, CR complete remission, PB peripheral blood, BM bone marrow, TCD T cell depletion, CMV cytomegalovirus